Wordt geladen...
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
Despite the proven effective approach to targeting the phosphatidylinositol-3-kinase (PI3K) pathway in B-cell malignancies, the approved PI3K inhibitors idelalisib and duvelisib have been less commonly selected for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), give...
Bewaard in:
| Gepubliceerd in: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727518/ https://ncbi.nlm.nih.gov/pubmed/33275709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000119 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|